Kornimate/medical-research-clean huggingface dataset:
study using spray skin protector versus conventional treatment to prevent acute radiodermatitis.

Conditions: Radiodermatitis; Injury, Radiation

Summary: this is a randomized, open-label, single-institution trial designed to evaluate the effectiveness of a spray skin protector in preventing moist desquamation caused by radiotherapy treatment. this technology, spray skin protection, depending on the manufacturer, is primarily intended to prevent or reduce contact dermatitis. however, this study will be evaluated for use in preventing moist desquamation caused by ionizing radiation. the comparing agent will be a moisturizer, agreed upon at the local institution of the study for use in the prevention of radiodermatitis. as secondary objectives: describe adverse events, diarrhea, pain and pruritus. the study will be conducted at the radiotherapy outpatient clinic of the cancer hospital i (hci) of national cancer institute (inca) in brazil.

the hypotheses are: null (ho): the incidence of moist desquamation with the spray skin protector is greater than or equal to the incidence of moist desquamation in the control group. alternative (h1): the incidence of moist desquamation with the spray skin protector is lower than the incidence of moist desquamation in the control group. the evaluation of the skin of the participants will be weekly, with blinding of this professional. for the evaluation of secondary objectives, adverse events will be applied in the assessment scales of diarrhea, pruritus and pain by the ctcae version 5.0; and the burning or burning sensation will be recorded only.

Eligibility criteria:
inclusion criteria: patients with anal and rectal cancer with indication for radiotherapy and conventional fractionation of treatment in a linear accelerator; age \> or = 18 years; no previous history of radiotherapy in the same field/site of treatment (reirradiation). - exclusion criteria:patients with pre-existing irradiated dermatitis, which makes skin assessment difficult; previous report of allergic reaction to any of the products used in the research. -

Keywords: barrier film spray skin protection liquid-film barrier product
treatment for patellofemoral pain syndrome using footwear

Conditions: Patellofemoral Pain Syndrome

Summary: patellofemoral pain syndrome (pfps) is the most common running injury and is believed to be associated with higher than normal knee joint loading. footwear has been developed that may decrease these knee loads in healthy subjects, but their effects on patients with pfps are unknown. in this study, we aim to test the effects of such footwear on patients with pfps. we hypothesize that patients who receive the footwear intervention will show a decrease in knee joint loading, and consequently will show improvements in subjective levels of perceived knee pain over a period of six weeks compared to a control condition.


Eligibility criteria:
inclusion criteria: * male or female between 18 and 45 years of age. * have been diagnosed with patellofemoral pain syndrome (pfps) by a physician. * have nontraumatic unilateral and/or bilateral peripatellar or retropatellar knee pain. * patellofemoral knee pain with and/or after activity. * inactivity patellofemoral pain and/or stiffness, especially with sitting with knees held in flexed posture. * peripatellar tenderness ± mild inferior patellar pole tenderness. * run at least 15km per week. * are heel-toe runners (as opposed to forefoot strikers). exclusion criteria: * are currently, or have previously, participated in any other forms of treatment for their knee pain. * significant articular or periarticular effusion or bursitis. * significant joint line tenderness. * intra-articular ligamentous instability. * patellar apprehension. * have undergone any form of knee surgery or arthroscopy. * have any other neuromuscular, musculoskeletal or cardiovascular conditions

Keywords: footwear motion analysis running injury
orange juice consumption and cognitive function

Conditions: Nerve Degeneration

Summary: this study is investigating the effect of 8 weeks of orange juice supplementation on executive function in healthy older adults. the study is a controled, double-blind, crossover trial and involves a 8 week supplementation with a high flavonone orange juice and a carbohydrate-matched control. volunteers consume 500ml of either the test juice or the control juice per day for an 8 week period. there is then an 8 week washout period before subjects proceed to the other arm of the study. subjects are randomly assigned to either arm at the beginning of the study. measures of cognitive function will be administered pre and post both test and control interventions. blood pressure will also be measured and blood and urine samples will be collected to assess absorption of from the juice. a sub-sample of volunteers will undergo mri imaging pre- and post intervention to acquire cerebral blow flow information.


Eligibility criteria:
inclusion criteria: * in good general health i.e. no major health condition such as diabetes * bmi \< 30 * cholesterol \< 6 and bp \< 150/90 * not on blood pressure medication or blood thinning medication such as aspirin - no learning difficulty such as dyslexia exclusion criteria: * diabetes * gastro-intestinal disease * high bmi * cholesterol and bp * smoker * on blood pressure medication or blood thinning medication such as aspirin * dyslexic/dyspraxic * depression or history of depression

Keywords: orange juice cognitive function flavonoids flavanones
modified perineal linear stapler resection for external rectal prolapse: a novel approach

Conditions: Rectal Prolapse

Summary: from december 2016 to july 2019, 36 elderly co-morbid patients with rectal prolapse were involved in this study which is performed in the git surgery unit of zagazig university hospital. the investigators used a modified linear stapler resection technique for the rectal prolapse. postoperative follow up was done for one year to evaluate functional outcome, operative time, hospital stay and complications

the study was done in the git unit of the general surgery department of zagazig university hospital in the period from december 2016 to july 2019. the hospital institutional review board approved the study protocol. thirty-six old, co-morbid and short life expectancy patients were included in the sample. they were evaluated for psp. informed consent was signed by all patients or first-degree relatives after full discussion of the advantage and disadvantage of the operation. preoperative bimanual examination was done for rectal prolapse to rule out enterocele or cystocele and this was confirmed by mri. the routine preoperative evaluation was done for all patients (physical examination, complete blood tests, ecg and chest x-ray). bowel preparation was done for all patients. regarding bowel function, all patients were evaluated for fecal incontinence by wexner score and for constipation by rome ii criteria. prophylactic intravenous cephalosporin and metronidazole was given one hour before operation. the operation was done under spinal anesthesia in the lithotomy position with slight trendeleburg to prevent trapping of abdominal organs between walls of rectum. all operations were done by the same surgical members of the unit. hospital stay, intraoperative and postoperative complications were recorded. all patients started oral fluids in the second day. follow up was done for patients every 1,3,6,9 and 12 months in the outpatient clinic.

Eligibility criteria:
inclusion criteria: * old age * complete rectal prolapse * co-morbid asa i to iii exclusion criteria: -
contemporary clinical management of acute pulmonary embolism

Conditions: Acute Pulmonary Embolism

Summary: acute pulmonary embolism is a potentially life-threatening disease with short-term mortality ranges from less than 1% to more than 30% during the hospital stay. recent guidelines recommend to tailor diagnosis hospitalization and acute treatment based on the estimated risk for short-term death. the assessment of the contemporary clinical management of patients with acute pulmonary embolism across different specialties would be of crucial value.

this is a prospective, non-interventional, multicenter study in patients with acute pulmonary embolism admitted to cardiology, emergency and internal medicine departments in italy. the aim of the study is to assess contemporary management strategies in patients with acute pulmonary embolism in terms of diagnosis, risk stratification, hospitalization and treatment in italy and assess 1. their association with in-hospital and 30-day mortality and 2. their adherence to current guidelines of the european society of cardiology (esc).

Eligibility criteria:
inclusion criteria: * patients with acute, symptomatic acute pulmonary embolism * age ≥ 18 years * informed consent exclusion criteria: * refusal of informed consent * participation in controlled trials on the management of patients with acute pulmonary embolism

Keywords: acute pulmonary embolism international guidelines
high agreement between the danish ventral hernia database and hospital files in region zealand

Conditions: Data Agreement Between a Database and Hospital Files After a Ventral Hernia Repair

Summary: is there agreement between data in the danish ventral hernia database and patient files


Eligibility criteria:
inclusion criteria: * all ventral hernia repairs
pre-operative bowel preparation prior to minimally invasive sacral colpopexy

Conditions: Pelvic Organ Prolapse; Prolapse

Summary: prior to surgery, gynecologists and urogynecologists have routinely prescribed preoperative mechanical bowel preparations in attempts to decrease the risk of infection, while also providing easier bowel manipulation and better visualization during surgery. however, many of these proposed benefits have never been proven, and usage of bowel preparations amongst surgeons remains highly variable. in both the general surgery and gynecology literature, researchers have begun to question the need for the vigorous preparations. aside from surgical visualization, urogynecologists have additional concerns about how bowel preparations may impact postoperative bowel function given up to half of women with pelvic floor disorders have baseline constipation and straining is known to impact surgical recovery. many studies have addressed various postoperative fiber and laxative preparations in attempts to improve postoperative bowel-related symptomatology, but none have specifically looked at preoperative bowel preparations. this study aims to determine if mechanical bowel preparation prior to minimally invasive sacral colpopexy affects patients' postoperative recovery, specifically related to bowel symptomatology; operative or post-operative complications; surgeons' perceptions of surgical difficulty directly attributed to the bowel; and post-operative return of normal bowel function.


Eligibility criteria:
inclusion criteria: * female * age ≥ 18 years * planned laparoscopic or robotic-assisted sacral colpopexy exclusion criteria: * history of ulcerative colitis or crohn's disease * prior large or small bowel resection * known diagnosis of gastroparesis * prior pelvic radiation * history of abdominal or pelvic malignancy * planned concurrent bowel surgery/anal sphincteroplasty/ rectovaginal fistula repair * pregnancy * known allergic reactions to components of the study products * known renal insufficiency * non-english speaking as the primary study questionnaires are all currently in english only

Keywords: pelvic organ prolapse prolapse cathartics mechanical bowel preparation
efficacy of behavioral therapy and exercise in gestational diabetes mellitus (gdm)

Conditions: Birth-weight

Summary: the purpose of the study is to test whether four lifestyle intervention programs (diet alone; diet and behavioral therapy, diet and exercise, diet and behavioral therapy and exercise), delivered to women with gdm during 24-26 weeks of gestational age will help women to improve their metabolic pattern, and decrease the incidence of adverse maternal and neonatal outcomes.

women with gestational diabetes (gdm) are at increased risk of adverse pregnancy and neonatal outcomes. it is estimated that most women diagnosed with gdm can achieve targeted glycemic goals with nutrition therapy alone. a moderate exercise is recommended to lower serum glucose and to improve insulin sensitivity. despite this, few reports examine the effect of exercise on glucose intolerance during pregnancy. furthermore, no trial on the efficacy of behavioral treatment in women with gdm is available. the purpose of the study is to test whether four lifestyle intervention programs (diet alone; diet and behavioral therapy, diet and exercise, diet and behavioral therapy and exercise), delivered to women with gdm during 24-26 weeks of gestational age will help women to improve their metabolic pattern, and decrease the incidence of adverse maternal and neonatal outcomes.

Eligibility criteria:
inclusion criteria: * gestational age between 24 and 26 weeks * diagnosis of gdm at the 75g oral glucose tolerance test (ogtt) * singleton pregnancy exclusion criteria: * body mass index \> 40 or \< 12kg/m2 * any known diseases (pre-existing diabetes mellitus, cardiovascular diseases, liver/kidney diseases, cancers, arterial hypertension) * patients on any drugs

Keywords: gestational diabetes mellitus fasting glucose insulin resistance birth-weight glucose values insulin concentrations cesarean sections
the china-anhui birth cohort study (c-abcs)

Conditions: Environmental Exposures; Other Pregnancy With Abortive Outcome; Birth Defects; Children Development

Summary: the china-anhui birth cohort study (c-abcs) was set up to examine the delayed, cumulative and interactive effects of maternal environmental exposures on birth outcomes and children's development. the c-abcs recruited pregnant women from six major cities of anhui province, china, between november 2008 and october 2010. a range of data (including demographic, obstetric, occupational, nutritional and psychosocial factors) were collected by both interviews and laboratory tests. in each trimester, women's blood samples were drawn, and pregnancy complications were abstracted from physician's medical records. by the end of 2011, birth outcomes/birth defects were observed/identified by clinicians within 12 months after the delivery of 11 421 singleton live births of six cities and those outcomes among the remaining 2033 live births are still being observed. in addition, 4668 children from ma'anshan city will be further followed up during the pre-school period till they reach adolescence to obtain the data on familial environmental exposures as well as children's physical, psychological, behavioural and sexual development. the interview data and information on laboratory examinations are available on request from archives in the anhui provincial key laboratory of population health \& aristogenics.


Eligibility criteria:
inclusion criteria: 1. having been lived in local city at least 6 months; 2. establishing maternal card in the hospital for the first time; 3. gestational week ≤ 16 weeks; 4. willing to have antenatal checkups and childbirth in the hospital where they establish maternal cards. exclusion criteria: 1. women who have abnormities in speaking and can not complete the survey by themselves; 2. women with mental disorders; 3. women who plan to leave local places.

Keywords: birth cohort study environmental exposures birth defects pregnant outcomes children development
comparison of efficacy and safety of prandilin and novorapid in newly diagnosed type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: to compare the effect of the rapid-acting insulin analogues (raias) novorapid (aspart) and prandilin (lispro) on glycemic variations by continuous glucose monitoring system (cgms) in continuous subcutaneous insulin infusion (csii) with metformin intensive therapy in newly diagnosed type 2 diabetes mellitus (t2dm).

the study was designed as a single blind randomized control trial. a total of 110 newly type 2 diabetic diagnosed patients with hemoglobin a1c (hba1c%) above 9% were hospitalized, and were randomly divided into two groups: novorapid group (group asp) and prandilin group (group lis) in csii, combined with metformin therapy. treatments were maintained for 2-3 weeks after the glycaemic target was reached. to complete the assessment of general information, fasting c-peptide (c-p0), 2-h postprandial c-peptide (c-p2h), fasting insulin (ins0), 2-h postprandial insulin (ins2h), hba1c% and fructosamine on the baseline and endpoint. 4 days continuous glucose monitoring (cgm) was performed on after three days stable glucose.

Eligibility criteria:
inclusion criteria: 1. voluntary to attend this study signed the informed consent; 2. between 18 and 75 years of age; 3. according to the who standards, the subjects should be newly diagnosed as type 2 diabetes; 4. bmi between 19 and 35kg/m2; 5.hba1c\>9%; 6. using enough contraception and not pregnancy; 7. the patients do not attend any medical subjectsin in the last 3 months before enrollment; 8. the subjects agreed to maintain the original diet and exercise habits throughout the study period. exclusion criteria: 1. patients with severe cardiopulmonary disease; 2. patients with acute complications (diabetic ketoacidosis, diabetic ketosis hypertonic coma, diabetes lactic acidosis, etc.); 3. patients with intolerance to metformin allergy to metformin 4. patients with history of mental disease, and not suitable for the use of insulin pump; 5. researchers think that the patients does not fit for this research (such as alcoholism, drug abuse, etc.).

Keywords: diabetes mellitus rapid-acting insulin analogues continuous glucose monitoring system (cgms) continuous subcutaneous insulin infusion (csii)
study to evaluate the safety of 3 new 6:2 influenza virus reassortants in adults for the 2015-2016 season

Conditions: Influenza; Healthy

Summary: this prospective annual release study is designed to evaluate the safety of 3 new influenza virus vaccine strains to be included in flumist quadrivalent for the 2015-2016 influenza season

this prospective, randomized, double-blind, placebo-controlled release study will enroll approximately 300 healthy adults 18 to 49 years of age. eligible participants will be randomly assigned in a 4:1 fashion to receive a single dose of trivalent vaccine or placebo by intranasal spray. randomization will be stratified by site. this study will be conducted at 3 sites in the united states of america. each participant will receive 1 dose of investigational product on day 1. the duration of study participation for each participant is the time from study vaccination through 181 days after study vaccination.

Eligibility criteria:
inclusion criteria: * age 18 through 49 years * written informed consent * participant available by telephone * ability to understand and comply with the requirements of the protocol, as judged by the investigator exclusion criteria: * concurrent enrollment in another clinical study up to 180 days after receipt of investigational product (day 181) * history of hypersensitivity to any component of the vaccine, including egg or egg protein or serious, life threatening, or severe reactions to previous influenza vaccinations * any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (example \[eg\], asthma), chronic metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year * acute febrile (greater than \[\>\] 100.0 degrees fahrenheit \[f\] oral or equivalent) and/or clinically significant respiratory illness (example, cough or sore throat) within 14 days prior to randomization * any known immunosuppressive condition or immune deficiency disease, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy * history of guillain-barré syndrome

Keywords: trivalent influenza flumist quadrivalent vaccine prevention healthy
effect of valsartan vs perindopril on homa-ir index in patients with chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: the purpose of this study is to compare the effect of valsartan and perindopril on homa-ir index in patients with chronic kidney disease.

eligiable volunteers are administrated single-dose over the period i and ii (crossover) of valsartan (80mg) as of perindopril (4mg). every time before and after each medication, homa-ir index and other parameters and safety of valsartan (80mg) and perindopril (4mg) is performed using a blood sample and conducting some tests (vital signs, physical exam, ecg, laboratory test, etc.) respectively.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic kidney disease * serum creatinine:1\~3mg/dl exclusion criteria: * diabetes * patients treated with corticosteroids or immunosuppressants * bmi\>30kg/m2 * sp\>180mmhg, dp\>110mmhg * patients with serious medical problems requiring specific medical treatment

Keywords: chronic kidney disease, anti-hypertensive drugs
role of arni in ventricular remodeling in hypertensive lvh

Conditions: Hypertensive Heart Disease

Summary: in singapore, hypertension is very common in the adult population. hypertensive heart disease is a leading cause of heart failure and cardiovascular death. current management relies primarily on achieving blood pressure targets. however, the optimal blood pressure goals are controversial and there are inherent difficulties in measuring blood pressure using external devices applied to peripheral arteries. as a result of (usually longstanding) hypertension, the heart thickens (i.e. hypertrophies) to maintain function. ultimately, hf may occur due to long standing energy deficits, muscle injury/death and diffuse interstitial fibrosis (heart muscle scarring). in an ongoing study (remodel, clinicaltrial.gov identifier nct02670031), we have been able to undertake preliminary analyses with respect to factors associated with the development of fibrosis. in this randomize controlled trial, we will be examining a novel therapy that has the potential to induce regression cardiac hypertrophy and fibrosis.


Eligibility criteria:
inclusion criteria: * increased left ventricular mass on cardiovascular magnetic resonance (based on established local age- and sex-specific cmr ranges) * essential hypertension exclusion criteria: * known secondary causes of hypertension * previous intolerance to angiotensin receptor blockers * history of heart failure * stage iv/v chronic renal disease (egfr \< 30ml/min/1.73m2) * patients with serum potassium \> 5.2 mmol/l (meg/l) at visit 1 * history of cardiovascular events (myocardial infarction, strokes and transient ischemic attacks) * known atrial fibrillation * being unable to understand or comply with study procedures (including cmr) * history or presence of any other disease with a life expectancy of \< 3 years * pregnant or nursing (lactating) women